Insider Cluster (1 insider) ·Filed Mar 6, 2026

NUVL

Nuvalent, Inc.
NEUTRAL
Impact 4/10
Horizondays Processed6mo ago
Insider cluster: 2 insiders, $3.7M total
Actionable Insight • Neutral

Monitor for additional insider sales or commentary around upcoming earnings or clinical trial updates; current activity is within normal range for a mid-cap biotech executive but warrants attention if trend continues.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
NUVL ▼ -6.44% at T+60d
NEUTRAL call ✗ call lost -6.44% · α vs SPY -19.22% · entry $99.41 → $93.01
Entry anchored
Mar 5, 03:59 PM ET
via exchange tick
T+1d
+2.93%
call +2.93% · α +2.08%
$102.32
settled 7mo ago
T+5d
-1.49%
call -1.49% · α +0.04%
$97.93
settled 7mo ago
T+20d
+4.33%
call +4.33% · α +6.37%
$103.71
settled 6mo ago
T+60d
-6.44%
call -6.44% · α -19.22%
$93.01
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

Nuvalent's Chief Scientific Officer, Henry E. Pelish, sold 24,993 shares in open-market transactions over two days, realizing approximately $2.44 million in proceeds. The sales were accompanied by the exercise of derivative securities for 16,912 shares, with minimal cash outlay. The total open-market sell value represents a small fraction of Nuvalent's $7.7B market cap.

Key Financial Metrics

Direction
selling
Total Value
$2.4M
Insiders
1

Key Facts

  • Chief Scientific Officer Henry E. Pelish sold 24,993 shares in open-market transactions on March 12 and 13, 2026, for total proceeds of $2,444,145.87.
  • Pelish also exercised derivative securities for 16,912 shares, with a nominal cost of $160,072.08 and one tranche at $0 (non-cash).
  • Total open-market sale value: ~$2.44M, representing 0.03% of Nuvalent’s $7.7B market cap.
  • All transactions were reported on Form 4 and appear to be part of a pre-arranged trading plan or portfolio diversification.

Financial Impact

$2.44 million in open-market share sales by a C-suite executive

insider ownershipshare countpotential sentiment

Risk Factors

  • Perception of insider confidence erosion if further sales occur.
  • Potential for short-term stock price sensitivity if market misinterprets the sales as negative signal.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CONTEXT: Insider Cluster Data (4 trades, 7d window)cluster-NUVL-1773693145016
18 reports for NUVL
Performance horizon
38% Hit rate 3 of 8 directional calls best @ T+60▲ +21.01%Apr 7, 2026
Filters
Rows
Reports for NUVL — sortable, filterable
TypeNow
Jul 27, 2026
9w ago
15-12G
NEUTRAL ★ 3/10
—awaiting T+5——
Jul 15, 2026
11w ago
25-NSE
NEUTRAL ★ 3/10
$123.96 $123.96· 0.00%▲ +0.98%—
Jul 15, 2026
11w ago
8-K
BULLISH ★ 5/10
$123.96 $123.96· 0.00%▲ +0.98%—
Jul 8, 2026
12w ago
Insider Cluster
NEUTRAL ★ 3/10
$123.80 $123.96▲ +0.13%▼ −0.73%—
Jul 6, 2026
12w ago
Insider Cluster
NEUTRAL ★ 3/10
$123.72 $123.90▲ +0.15%▼ −0.34%—
Jun 11, 2026
16w ago
Insider Cluster
NEUTRAL ★ 2/10
$123.25 $123.43▲ +0.15%▼ −0.53%—
Jun 10, 2026
16w ago
Insider Cluster
NEUTRAL ★ 3/10
$123.45 $123.36▼ −0.07%▼ −0.51%—
Jun 9, 2026
16w ago
8-K
BULLISH ★ 8/10
$123.25 $123.35▲ +0.08%▼ −2.33%—
May 7, 2026
21w ago
8-K
NEUTRAL ★ 4/10
$102.40 $105.22▲ +2.75%▲ +1.25%—
Apr 29, 2026
22w ago
Insider Cluster
NEUTRAL ★ 2/10
$99.10 $101.47▲ +2.39%▼ −0.72%—
Showing 10 of 18

US Market Status

Market Open — Closes in 3h 55m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Mar 16, 2026